Colon cancer surveillance in inflammatory bowel disease patients: Current and emerging practices

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 6, 2008, Pages 817-825

  Velayos, Fernando ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemoprevention; Chromoendoscopy; Colon cancer; Colonoscopy; Dysplasia

Indexed keywords

ACETYLSALICYLIC ACID; FOLIC ACID; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; URSODEOXYCHOLIC ACID;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CHROMOENDOSCOPY; COLON BIOPSY; COLON CARCINOGENESIS; COLON POLYP; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; DRUG EFFICACY; ENTERITIS; GASTROINTESTINAL DYSPLASIA; HUMAN; MALIGNANT TRANSFORMATION; POLYPECTOMY; PROCTOCOLECTOMY; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING TEST; ULCERATIVE COLITIS; BIOPSY; COLON TUMOR; GASTROINTESTINAL ENDOSCOPY; PATHOLOGY;

BIOPSY; COLONIC NEOPLASMS; COLONOSCOPY; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS;

EID: 61549105322     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.6.817     Document Type: Review

References (63)

1. Crohn B, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am. J. Med. Sci. 170, 220-227 (1925).
2. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment. Pharmacol. Ther. 23(8), 1097-1104 (2006).
3. Clevers H. Colon cancer - understanding how NSAIDs work. N. Engl. J. Med. 354(7), 761-763 (2006).
4. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48(4), 526-535 (2001).
5. Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TI. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am. J. Gastroenterol. 100(12), 2724-2729 (2005).
6. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 323(18),1228-1233 (1990).
7. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin. Gastroenterol. Hepatol. 2(12), 1088-1095 (2004).
8. Jess T, Loftus EV, Velayos FS et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 130(4), 1039-1046 (2006).
9. Delaunoit T, Limburg PJ, Goldberg RM, Lymp JF, Loftus EV Jr. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4(3), 335-342 (2006).
10. Itzkowitz S. Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice. J. Clin. Gastroenterol. 36(5 Suppl.), S70-S74; discussion S94-S96 (2003).
11. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126(6), 1634-1648 (2004).
12. Brentnall TA, Crispin DA, Rabinovitch PS et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107(2), 369-378 (1994).
13. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 287(1), G7-G17 (2004).
14. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest. Endosc. 56(1), 48-54 (2002).
15. Askling J, Dickman PW, Karlen P. Family history as a risk factor for colorectal cancel in inflammatory bowel disease. Gastroenterology 120(6), 1356-1362 (2001).
16. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case - control study. Aliment. Pharmacol. Ther. 14(2), 145-153 (2000).
17. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case - control study. Gastroenterology 107(1), 117-120 (1994).
18. Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor fo colorectal neoplasia in ulcerative colitis. Gastroenterology 126(2), 451-459 (2004).
19. Rubin DT, Huo D, Rothe JA et al. Increased inflammatory activity is an independent risk factor for dysplasia and colorectal cancer in ulcerative colitis: a case - control analysis with blinded prospective pathology review. Gastroenterology 130(4), A2 (2006).
20. Bansal R, Itzkowitz S, Harpaz N et al. Severity of inflammation predicts progression to colorectal neoplasia in ulcerative colitis. Am. J. Gastroenterol. 100(9), S289 (2005).
21. Gupta RB, Harpaz N, Itzkowitz S et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133(4), 1099-1105 (2007).
22. Velayos FS, Loftus EV, Jess T et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case - control study. Gastroenterology 130(7), 1941-1949 (2006).
23. Siegel CA, BE Sands. Risk factors for colorectal cancer in Crohn's colitis: a case - control study. Inflamm. Bowel Dis. 12(6), 491-496 (2006).
24. Rutter MD, Saunders BP, Wilkinson KH et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 53(12), 1813-1816 (2004).
25. Heuschen UA, Hinz U, Allemeyer EH et al. Backwash ileitis is strongly ssociated with colorectal carcinoma in ulcerative colitis. Gastroenterology 120(4), 841-847 (2001).
26. Shelton AA, Lehman RE, Schrock TR, Welton ML. Retrospective review of colorectal cancer in ulcerative colitis at a tertiary center. Arch. Surg. 131(8), 806-810; discussion 810-811 (1996).
27. Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm. Bowel Dis. 11(3), 314-321 (2005).
28. Winawer S, Fletcher R, Rex D et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology. 124(2), 544-560 (2003).
29. Broomé U, Löfberg R, Lundqvist K, Veress B. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis. Colon Rectum. 38(12), 1301-1305 (1995).
30. Bernstein CN. A balancing view: dysplasia surveillance in ulcerative colitis - sorting the pro from the con. Am. J. Gastroenterol. 99(9), 1636-1637 (2004).
31. Choi PM, Nugent FW, Schoetz DJ, Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 105(2), 418-424 (1993).
32. Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 107(4), 934-944 (1994).
33. Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson P, Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 42(5), 711-714 (1998).
34. Connell WR, Talbot IC, Harpaz N et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut 35(10), 1419-1423 (1994).
35. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 343(8889), 71-74 (1994).
36. Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest. Endosc. 51(2), 123-128 (2000).
37. Rubin CE, Haggitt RC, Burmer GC et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103(5), 1611-1620 (1992).
38. Thomas T, Nair P, Dronfield MW, Mayberry JF. Management of low and high-grade dysplasia in inflammatory bowel disease: the gastroenterologists' perspective and current practice in the United Kingdom. Eur. J. Gastroenterol. Hepatol. 17(12), 1317-1324 (2005).
39. Rutter MD, Saunders BP, Wilkinson KH et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130(4), 1030-1038 (2006).
40. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 51 (Suppl. 5), V10-V12 (2002).
41. Woolrich AJ, DaSilva MD, Korelitz BI. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia. Gastroenterology 103(2), 431-438 (1992).
42. Eaden J, Abrams K, McKay H, Denley H, Mayberry J. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J. Pathol. 194(2), 152-157 (2001).
43. Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 125(5), 1311-1319 (2003).
44. Ullman TA, Loftus EV Jr, Kakar S, Burgart LJ, Sandborn WJ, Tremaine WJ. The fate of low grade dysplasia in ulcerative colitis. Am. J. Gastroenterol. 97(4), 922-927 (2002).
45. Lindberg B, Persson B, Veress B, Ingelman-Sundberg H, Granqvist S. Twenty years' colonoscopic surveillance of patients with ulcerative colitis. Detection of dysplastic and malignant transformation. Scand. J. Gastroenterol. 31(12), 1195-1204 (1996).
46. Befrits R, Ljung T, Jaramillo E, Rubio C. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis. Colon Rectum 45(5), 615-620 (2002).
47. Lim CH, Dixon MF, Vail A, Forman D, Lynch DAF, Axon ATR. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 52(8), 1127-1132 (2003).
48. Rubio CA. Serrated neoplasias and de novo carcinomas in ulcerative colitis: a histological study in colectomy specimens. J. Gastroenterol. Hepatol. 22(7), 1024-1031 (2007).
49. Ullman TA. Colonoscopic surveillance in inflammatory bowel disease. Curr. Opin. Gastroenterol. 21(5), 585-588 (2005).
50. Bernstein CN, Weinstein WM, Levine DS, Shanahan F. Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am. J. Gastroenterol. 90(12), 2106-2114 (1995).
51. Kiesslich R, Neurath MF. Surveillance colonoscopy in ulcerative colitis: magnifying chromoendoscopy in the spotlight. Gut 53(2), 165-167 (2004).
52. Hurlstone DP, McAlindon ME, Sanders DS, Keogh R, Lobo AJ, Gross SS. Further validation of high-magnification chromoscopic-colonoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 126(1), 376-378 (2004).
53. Kiesslich R, Fritsch J, Holtmann M et al., Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 124(4), 880-888 (2003).
54. Hurlstone DP, Sanders DS, Lobo AJ, Mcalindon ME, Cross SS. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy 37(12), 1186-1192 (2005).
55. Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 53(2), 256-260 (2004).
56. Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment. Pharmacol. Ther. 18(Suppl. 2), 10-14 (2003).
57. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol. 100(6), 1345-1353 (2005).
58. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am. J. Gastroenterol. 91(1), 44-48 (1996).
59. Tung BY, Emond MJ, Haggitt RC. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann. Intern. Med. 134(2), 89-95 (2001).
60. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124(4), 889-893 (2003).
61. Lashner B, Provencher K, Seidner D, Knesebeck A, Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 112(1), 29-32 (1997).
62. Kiesslich R, Goetz M, Angus EM et al. Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy. Gastroenterology 133(6), 1769-1778 (2007).
63. Katagiri A, Fu KI, Sano Y et al. Narrow band imaging with magnifying colonoscopy as diagnostic tool for predicting histology of early colorectal neoplasia. Aliment. Pharmacol. Ther. 27(12), 1269-1274 (2008).